{"id":"https://openalex.org/W2946976600","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2617","title":"Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.","display_name":"Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2946976600","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2617","mag":"2946976600"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.2617","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2617","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.2617","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043773782","display_name":"Vaia Florou","orcid":"https://orcid.org/0000-0001-5558-753X","observed_orcids":["https://orcid.org/0000-0001-5558-753X"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vaia Florou","raw_affiliation_strings":["University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL;","institution_ids":["https://openalex.org/I145608581","https://openalex.org/I4210157065"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033315908","display_name":"Wungki Park","orcid":"https://orcid.org/0000-0002-8006-3102","observed_orcids":["https://orcid.org/0000-0002-8006-3102"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wungki Park","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, Department of Medicine, Gastrointestinal Oncology, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, Department of Medicine, Gastrointestinal Oncology, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065012486","display_name":"Peter J. Hosein","orcid":"https://orcid.org/0000-0001-8537-6397","observed_orcids":["https://orcid.org/0000-0001-8537-6397"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Joel Hosein","raw_affiliation_strings":["University of Miami Sylvester Comprehensive Cancer Center, Miami, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Miami Sylvester Comprehensive Cancer Center, Miami, FL;","institution_ids":["https://openalex.org/I145608581","https://openalex.org/I4210157065"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004799762","display_name":"Breelyn Ann Wilky","orcid":"https://orcid.org/0000-0001-5080-497X","observed_orcids":["https://orcid.org/0000-0001-5080-497X"]},"institutions":[{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Breelyn A. Wilky","raw_affiliation_strings":["Sylvester Comprehensive Cancer Center, Miami, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sylvester Comprehensive Cancer Center, Miami, FL;","institution_ids":["https://openalex.org/I4210157065"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004418792","display_name":"Jonathan C. Trent","orcid":"https://orcid.org/0000-0001-6169-5238","observed_orcids":["https://orcid.org/0000-0001-6169-5238"]},"institutions":[{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan C. Trent","raw_affiliation_strings":["Sylvester Comprehensive Cancer Center, Miami, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sylvester Comprehensive Cancer Center, Miami, FL;","institution_ids":["https://openalex.org/I4210157065"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110575336","display_name":"Gilberto L Lopes Junior","orcid":"https://orcid.org/0000-0002-1151-9903","observed_orcids":["https://orcid.org/0000-0002-1151-9903"]},"institutions":[{"id":"https://openalex.org/I4210101935","display_name":"University of Miami Health System","ror":"https://ror.org/00zw9nc64","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935"]},{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gilberto Lopes","raw_affiliation_strings":["Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL;","institution_ids":["https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"2617","last_page":"2617"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/frameshift-mutation","display_name":"frameshift mutation","score":0.9599999785423279},{"id":"https://openalex.org/keywords/tumor-mutational-burden","display_name":"tumor mutational burden","score":0.9559999704360962},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8379999995231628},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.8349999785423279},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9539999961853027},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9070000052452087},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6949999928474426},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.996999979019165},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.5189999938011169},{"id":"https://openalex.org/keywords/neoantigens","display_name":"neoantigens","score":0.6830000281333923},{"id":"https://openalex.org/keywords/immunotherapy-response","display_name":"immunotherapy response","score":0.5910000205039978},{"id":"https://openalex.org/keywords/msk-impact","display_name":"MSK-IMPACT","score":0.734000027179718},{"id":"https://openalex.org/keywords/foundationone","display_name":"FoundationOne","score":0.7680000066757202},{"id":"https://openalex.org/keywords/pan-cancer-analysis","display_name":"pan-cancer analysis","score":0.5879999995231628},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.531000018119812},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.48500001430511475}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.926762580871582},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6668791174888611},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.6607826948165894},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6552571654319763},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.6479992270469666},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5820477604866028},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.5562915205955505},{"id":"https://openalex.org/C57742111","wikidata":"https://www.wikidata.org/wiki/Q7168","display_name":"Histology","level":2,"score":0.44635024666786194},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.43797796964645386},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43163052201271057},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4237651824951172},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4119884967803955},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.26738297939300537},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.18107447028160095}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.2617","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2617","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.2617","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2989946095","https://openalex.org/W2991257542","https://openalex.org/W2898456937","https://openalex.org/W4385880929","https://openalex.org/W3166270674","https://openalex.org/W2949644336","https://openalex.org/W4402561637","https://openalex.org/W2990002905","https://openalex.org/W4281673946","https://openalex.org/W2987116731"],"abstract_inverted_index":{"2617":[0],"Background:":[1],"ICI":[2,116],"benefit":[3,259],"certain":[4],"patients":[5,300,307],"(pts)":[6],"with":[7,40,110,251,334,346],"various":[8],"malignancies":[9],"and":[10,53,104,117,132,147,160,204,215,228,240,257,294,298,319,330],"discovering":[11],"biomarkers":[12],"for":[13,349],"response":[14,253],"is":[15,357],"an":[16],"active":[17],"research":[18],"field.":[19],"Recently,":[20],"higher":[21],"TMB":[22,105,143,148,285,293,296,311,328],"(top":[23,145],"20%":[24],"in":[25,43,72,81,271,288,337,344,353],"each":[26],"histology)":[27],"based":[28],"on":[29,76,342],"nonsynonymous":[30],"single":[31],"nucleotide":[32],"variants":[33],"from":[34],"MSK-IMPACT":[35],"was":[36,97,225,248],"shown":[37],"to":[38,62,101,283,306],"correlate":[39],"superior":[41,335],"survival":[42,158,162],"a":[44,289,354],"pancancer":[45],"cohort.":[46],"Fsindels":[47],"may":[48],"generate":[49],"more":[50,133],"immunogenic":[51],"neoantigens":[52],"robust":[54],"T":[55],"cell":[56],"infiltrates,":[57],"thus":[58],"predicting":[59],"better":[60,303],"responses":[61],"ICI.":[63,77],"We":[64,123],"previously":[65,107],"demonstrated":[66],"the":[67,95,234,284],"clinical":[68,258],"implication":[69],"of":[70,94,245,292,327],"fsindel":[71,103,130,136,246,331],"lung":[73,172,350],"cancer":[74,173,340],"pts":[75,125,170,208,219,341],"However,":[78,287],"its":[79],"value":[80],"other":[82],"solid":[83,112,339],"cancers":[84,113],"has":[85],"not":[86,266],"been":[87],"evaluated.":[88],"Methods:":[89],"Comprehensive":[90],"genomic":[91],"profiling":[92],"(CGP)":[93],"tumors":[96],"performed":[98],"by":[99],"FoundationOne":[100],"derive":[102],"as":[106],"described.":[108],"Pts":[109],"advanced":[111,338],"who":[114,308],"received":[115,209],"had":[118,220,301,309],"CGP":[119],"available":[120],"were":[121,140,164,174,177,231,238],"included.":[122,175],"categorized":[124,141],"into":[126,142],"two":[127],"groups;":[128],"0":[129],"(FS-)":[131],"than":[134],"1":[135],"(FS+).":[137],"Also,":[138],"they":[139],"high":[144,297,312,329],"20%)":[146],"low":[149,318],"(bottom":[150],"80%)":[151],"within":[152],"their":[153],"own":[154],"histology.":[155],"Progression":[156],"free":[157],"(PFS)":[159],"overall":[161,252],"(OS)":[163],"compared.":[165],"Results:":[166],"One":[167],"hundred":[168],"thirty-one":[169],"excluding":[171],"There":[176],"11":[178],"histology":[179],"groups:":[180],"14":[181],"soft":[182],"tissue":[183],"sarcomas,":[184],"19":[185],"GU,":[186],"23":[187,189],"GI,":[188],"skin,":[190],"10":[191,193],"HEENT,":[192],"RCC,":[194],"9":[195],"GYO,":[196],"6":[197],"pancreas,":[198],"5":[199],"mucosal":[200],"melanoma,":[201],"4":[202],"breast,":[203],"8":[205],"others.":[206],"74":[207,237],"pembrolizumab,":[210],"25":[211],"nivolumab,":[212],"29":[213],"ipilimumab/nivolumab,":[214],"3":[216],"atezolizumab.":[217],"All":[218],"metastatic":[221],"disease,":[222],"mean":[223],"age":[224],"61":[226],"years":[227],"55":[229],"(42%)":[230],"women.":[232],"Among":[233],"131":[235],"pts,":[236],"FS-":[239],"57":[241],"FS+.":[242],"The":[243],"presence":[244],"(FS+)":[247],"significantly":[249,302],"correlated":[250,333],"(p":[254,261,273,278,321],"=":[255,262,274,279,322],"0.032)":[256],"rates":[260],"0.025).":[263],"TMB-high":[264],"did":[265],"show":[267],"any":[268],"significant":[269],"difference":[270],"PFS":[272,304,336],"0.1)":[275],"or":[276,313,315],"OS":[277],"0.28)":[280],"when":[281],"compared":[282,305],"low.":[286],"combined":[290],"model":[291,326],"fsindel,":[295],"FS+":[299,314],"either":[310],"neither":[316],"(TMB":[317],"FS-)":[320],"0.021).":[323],"Conclusions:":[324],"Combined":[325],"(+)":[332],"ICI,":[343],"concordance":[345],"previous":[347],"report":[348],"cancer.":[351],"Validation":[352],"larger":[355],"cohort":[356],"underway.":[358]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2019-06-07T00:00:00"}